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Abstract
Recombinant adeno-associated virus (rAAV) is a promising vector for retinal application as it transduces photoreceptors and
retinal pigment epithelium cells efficiently and in a stable fashion. Because rAAV also transduces retinal ganglion cells, we
reasoned that ocular application of rAAV might result in delivery of transgenic protein to the CNS. Here we describe high levels
of green fluorescent protein (GFP) persisting at least 6 months in optic nerves and brains of mice and dogs after intravitreal
delivery of rAAV–GFP. There was no clinical or histological evidence of inflammatory response although a mild humoral Th-2
response to viral capsid proteins was detected. These findings have important implications with respect to therapeutic applications
of rAAV. © 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Recombinant adeno-associated virus (rAAV)
promises to be a useful vector for retinal application as
it is replication-defective, has not been associated with
any human disease and transduces photoreceptors and
retinal pigment epithelium (RPE) cells efficiently and in
a stable fashion. Because rAAV also transduces retinal
ganglion cells (although at low levels) (Bennett, Duan,
Engelhardt & Maguire, 1997), we reasoned that ocular
application of rAAV might result in delivery of trans-
genic protein to axons projecting from these cells—ax-
ons which travel through the optic nerve to various
tracts in the brain. The ability to access the brain
through a single intraocular injection would invite a
number of scientific and clinical applications. Such
applications could range from studies delineating fine
anatomical pathways between the eye and the brain to
non-invasive delivery of experimental:therapeutic
molecules to internal brain structures. Here we describe
high levels of the green fluorescent protein (GFP) in the
optic tracts of the brain after intraocular delivery of
rAAV containing the cDNA encoding GFP (AAV–
GFP). Experiments were performed in cohorts (60
mice:120 eyes) of C57Bl:6 mice. In order to establish
generality of the result, experiments were performed in
a smaller number of eyes in a second species (two
dogs:four eyes). The dog eye is anatomically more
similar to the human eye than the mouse eye (it is
larger, has a cone-enriched region analogous to the
macula and has a holangiotic blood supply). In both
mice and dogs, GFP was detected in the central ner-
vous system (CNS) tissues known to be enervated by
retinal ganglion cells (Glaser & Sadun, 1990). GFP was
stable, with high levels detectable at the longest time-
points (6 months). Neither the rAAV nor presence of
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GFP resulted in clinical or histological evidence of
inflammatory response. Although animals developed
antibodies to viral capsid proteins, they did not develop
transgene-specific antibodies. The studies indicate that
toxicity studies of rAAV-mediated retinal gene therapy
should assess the possibility that intraocular delivery of
AAV can result in delivery of the transgene product
from the retina to the brain.
2. Methods
2.1. Virus preparation
AAV–GFP was prepared by packaging the recombi-
nant DNA into AAV particles by complementation
with a system expressing AAV rep and cap genes in
Ad-lacZ-infected 293 cells (Bennett et al., 1997; Duan,
Fisher, Burda & Engelhardt, 1997). The transgene cas-
sette consisted of the EGFP variant of the GFP cDNA
(Clontech, Palo Alto, CA) under control of a cy-
tomegalovirus (CMV) promoter. Titer of the purified
virus was determined by infectious unit assay on 293
cells and by slot blot for virion DNA particles. Purified
rAAV–GFP was tested for adenovirus contamination
as described (Bennett et al., 1997). No adenovirus was
detected. The AAV–GFP was also tested for contami-
nation with wild type AAV. This was performed by
infecting 293 cells with rAAV–GFP in the presence of
adenovirus and analyzing DNA harvested from the
resulting lysate by Southern analysis using a Rep probe.
Rep, reflecting the presence of wild-type AAV, was
variably detected, never at levels greater than 0.1%.
Ad.CMVGFP, which contains the same promoter
and transgene cassette as the rAAV–GFP, was purified
to 51011 pfu ml1 from 293 cells as described.
Aliquots of virus were tested for the presence of con-
taminating wildtype adenovirus by PCR amplification
of the adenovirus E1a region (deleted from the recom-
binants) as described (Bennett, Zeng, Bajwa, Klatt, Li
& Maguire, 1998). No contaminating virus was
detected.
2.2. Intraocular administration of recombinant 6irus
All animals were cared for in accordance with the
ARVO Statement for the Use of Animals in Oph-
thalmic and Vision Research, with federal, state and
local regulations and in accordance with the European
Communities Council Directive of 24 November 1986
(86:609:EEC). The minimal number of animals was
used to obtain statistically significant results. Studies
were performed on a large number of mice (n60) in
order to obtain statistically significant results. A smaller
number of dogs (n6) was used to determine whether
the results in mice were specific to that species or to the
type of surgical approach necessary in the small mouse
eye. An additional advantage of the dog is that intraoc-
ular fluid can be tapped from the dog eye (but not in
the small mouse eye) in order to evaluate intraocular
antibody response.
2.2.1. Mice
Injections were performed through a transscleral
transchoroidal approach as described. Subretinal and
intravitreal administration of 1–2 ml of infection solu-
tion (containing totals of 5108 infectious units (iu)
(or 3109 particles) of AAV–GFP or 5108 pfu (or
5109 particles) of Ad.CMVGFP) were performed.
Contralateral eyes were used as control. Cohorts of ten
adult mice (6–8 week old immunocompetent C57Bl:6
mice) were used in experiments evaluating each virus
and also in side-by-side comparisons of the two viruses.
Sham injection, injections of buffer alone and injec-
tions of rAAV containing the human bcl-2 cDNA
instead of GFP (AAV.bcl-2) were performed as con-
trols. Experiments were repeated four times.
2.2.2. Dogs
Injections of rAAV–GFP were performed in two
2.25 month old dogs with phenotypically wildtype reti-
nas. One eye of each dog received a subretinal injection
and the contralateral eye received an intravitreal injec-
tion. Each eye received a total of 2.41011 iu except
for one eye which received 1.21010 iu. The eye which
received the lower dose was one which was injected
subretinally. In summary, the total dose of one dog
(dog c1219) was 4.81011 iu (half intravitreally, half
subretinally) and that of the other dog (dog c1400),
2.51011 iu (2.41011 intravitreally and 1.21010
subretinally). Control intravitreal and subretinal injec-
tions of vehicle alone were performed in eyes of addi-
tional animals (n4 for each type of injection) of the
same age. The details of the surgical procedures are as
follows: dogs were pre-anesthetized with pre-acepro-
mazine, 0.1–0.3 mg kg1 IM then atropine 0.04 mg
kg1 IM. Induction (after aseptic preparation of the
site of venipuncture) was with thiopental, 1cc:6 lbs IV
of a 2% solution. This was followed by intubation and
ventilation with 2.5% isofluorane. The pupils were di-
lated with mydriacyl (tropicamide) 1% and mydfin
(phenylephrine hydrochloride) 2.5% and a fornix-based
conjunctival peritomy was performed in one quadrant
to expose the underlying sclera. The external sclera was
lightly treated with cautery at the incision site. An
anterior chamber paracentesis was performed with a 30
gauge needle to soften the eye prior to injection and to
obtain fluid for baseline intraocular antibody measure-
ments. A 30 gauge anterior chamber cannula (Storz)
was inserted through a sclerotomy 2 mm posterior to
the limbus at the 2:00 position and a 27 gauge needle
was used to incise the sclera approximately 2 to 3 mm
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posterior to the corneoscleral limbus. A 30 gauge blunt-
tipped anterior chamber infusion cannula was intro-
duced through the scleral incision into the vitreous.
While under direct visualization with an operating mi-
croscope and a plano convex fundus contact lens,
purified rAAV–GFP was injected into the vitreous
(0.25 ml containing 9.41010 iu) or into the subretinal
space (0.05 ml containing 1.91010 iu) of the non-
tapetal retina. Retinal vessels remained well perfused
during and following the procedure.
2.3. In 6i6o assessment of GFP expression
Animals were monitored for GFP expression by indi-
rect ophthalmoscopy at weekly intervals following in-
jection as described (Bennett et al., 1997). Fundus
photographs were taken with a Kowa camera (Keeler
Instruments, Broomall, PA) equipped with a Wratten
c47B gelatin excitation filter (Kodak, Rochester, NY).
2.4. Histological analyses
2.4.1. Mice
At necropsy, animals were perfused with 4%
paraformaldehyde and eyes and brains were fixed in
this same fix for 24 h at room temperature under
vacuum. Tissue was cryoprotected through successive
incubations (12 h each under vacuum) in 10, 20 and
30% sucrose (w:v) dissolved in saline.
2.4.2. Dogs
A 1 cm incision was made at the corneal limbus at
the time of enucleation and eyes were fixed in 4%
paraformaldehyde for 4 h on ice. Eyecups were dis-
sected away from the anterior segment and the lens and
vitreous were removed. Ocular tissue was fixed for an
additional 24 h at room temperature under vacuum.
The brain was immersed in 4% paraformaldehyde at
4°C at necropsy and was fixed intact under vacuum for
4 days. Dog eyes and brain were cryoprotected in a
similar mode as the mouse tissue except that samples
were immersed in each successive solution change for
24 h. Brains were bisected and each half was cut into
four separate blocks.
Tissues were immersed in optimal temperature com-
pound (O.C.T., Baxter) and frozen in dimethylpentane
in a dry ice bath. Serial sections were cut at 10–30 mm
on a Reichert–Jung cryostat at 23°C. GFP was
detected in whole mount tissue using an inverted Nikon
diaphot microscope equipped with FITC filters or in
tissue sections using a Leica DMXRE microscope
(equipped with the same filters). Adjacent sections were
observed under bright field after staining with hema-
toxylin and eosin in order to evaluate presence of
inflammatory cells.
2.5. Enzyme-linked immunoabsorbant assay (ELISA)
Samples were analyzed for antibodies to viral capsid
proteins using ELISA. Enhanced protein binding
ELISA plates were coated overnight at 4°C with anti-
gen (purified AAV) and then washed, blocked and
incubated with diluted (1:100, 1:400, 1:1600) serum or
intraocular fluid. Saline was used as negative control
for the mice. Serum from a human patient previously
found to have high levels of anti-AAV antibodies (CF
493 c31, kindly provided by N. Chirmule) was used as
a positive control. Samples were incubated with a 1:
1000 dilution of a peroxidase-conjugated goat-a-mouse
IgG (Jackson ImmunoResearch, 100 ml:well) and
washed. The Peroxidase Substrate System (Kirgaard &
Perry Laboratories) was used for the color reaction and
the plates were read at an optical density of 405 nm.
Measurements were repeated three times.
2.6. Western analysis
Humoral immune response to GFP was assessed by
Western blot analysis using modifications of techniques
described by Bennett, Pakola, Zeng and Maguire, 1996.
The modifications are as follows: each lane of a discon-
tinuous SDS (0.04%)–polyacrylamide (10%) 1 mm ana-
lytical gel was loaded with 1 mg purified EGFP
(Clontech). After transfer to nitrocellulose and division
of nitrocellulose into vertical strips, each strip was
exposed to the primary ‘antibody’ solution (5 ml of the
appropriate serum sample diluted 1:250) in blocking
buffer at 4°C for 12 h. After washing, strips were
incubated with the secondary antibody, peroxidase-la-
beled anti-mouse or anti-dog antibody (Jackson Im-
munoresearch) diluted 1:1000 for 1 h at room
temperature. Negative control ‘primary antibodies’ con-
sisted of naive mouse and dog serum. Positive controls
consisted of strips incubated with a GFP polyclonal
antibody (diluted 1:250; Clontech, Palo Alto, CA).
After application of the secondary antibody, the
blots were washed and peroxidase activity was mea-
sured after reaction with the ECL Western detection kit
(Amersham, Arlington Heights, IL) according to the
manufacturer’s directions.
3. Results
3.1. In 6i6o assessment of GFP fluorescence
GFP was not detected ophthalmoscopically in AAV–
GFP-injected eyes until 2–3 weeks after injection as
described previously (Bennett et al., 1997). At that time,
fluorescence was weak. As described previously in mice,
in both mice and dogs, regions with localized GFP
fluorescence were observed in eyes that had received
Fig. 1. Subretinal injection of AAV–GFP results in ophthalmoscopically detectable transgene expression 6 weeks after injection in mice and dogs.
(A) GFP is apparent in the right eye of a mouse which had received subretinal injection of AAV–GFP with blue light illumination. The left eye
(non-fluorescent) had received an injection of the vehicle alone. (B) Fundus view of ‘green’ eye depicted in (A). Ophthalmoscopic appearance of
dog eyes that had received subretinal (C) or intravitreal (D) injection of AAV–GFP. Eyes were photographed 6 weeks after injection. Arrows in
(C) and (D) indicate regions of fluorescence (more intense after subretinal injection).
Fig. 2. AAV–GFP transduces different subsets of retinal cells after subretinal and intravitreal injection in mice. Photoreceptor cells possess high
levels of GFP 2 months after subretinal injection of AAV–GFP. (A) Light microscopic and (B) fluorescence views; GFP-expressing ganglion cells
(arrows) are visible in panel D (brightfield view is shown in (C)). Outer segment structures possess mild autofluorescence (not GFP expression).
Fig. 3. Caption oppisite.
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subretinal injections. Although there was variability
from eye to eye, GFP expression in mice receiving
subretinal injection was often intense enough at 6 weeks
to detect by illuminating the animal with blue light
(Fig. 1A). Examination of these animals with illumina-
tion through a lens revealed widespread green fluores-
cence (Fig. 1B). Levels remained stable through the 8
month timepoint (termination of the experiment). No
fluorescence was detected in control retinas at any
timepoint. Fluorescence was not detected ophthalmo-
scopically after intravitreal injection in mice.
Because of the reflective tapetum in the dog (but not
the mouse), GFP fluorescence did not contrast as
sharply with the background pigmentation in the dog
as in the mouse. A representative photograph from a
dog eye showing a patch of fluorescing retina 6 weeks
after subretinal injection of AAV–GFP is shown in
Fig. 1C. Fluorescence was much more subtle and dif-
fuse in eyes receiving intravitreal injection (Fig. 1D;
arrow indicates small patch of fluorescing cells). As
with the mouse, ophthalmoscopically detectable GFP
fluorescence peaked by 6 weeks after injection in dog
eyes that received subretinal injection. Levels remained
stable through 23 weeks after injection without diminu-
tion (longest timepoint). There was no evidence of GFP
expression in eyes which were used as control or in
anterior segment structures of AAV-GFP-injected eyes.
There was no clinical evidence of inflammation or
discomfort in mice or dogs at any point after injection
of AAV–GFP. Corneas and media remained clear fol-
lowing injection, there was no excessive tearing, con-
junctiva remained uninjected and animals maintained
normal levels of activity and consumption of food and
water.
3.2. E6aluation of ocular tissue by microscopy
Confirmation of cellular specificity and location of
fluorescence was made histologically after tissue har-
vest. After subretinal injection of rAAV–GFP the pre-
dominant cell types expressing GFP were those of the
outer retina (photoreceptors and RPE cells), as de-
scribed previously (Bennett et al., 1997). Large patches
of fluorescing photoreceptors were observed in mice
and dogs (Fig. 2A, B; Fig. 4A). Fluorescence in under-
lying RPE cells was often intense (not shown). GFP
expression was not detected in photoreceptors or RPE
cells outside of the region of subretinal injection. How-
ever, those regions possessed occasional GFP-express-
ing ganglion cells (Bennett et al., 1997).
Intravitreal injection of rAAV–GFP resulted in
transgene expression only in ganglion cells and cells of
the inner retina in mice and dogs (Fig. 2C, D; Fig. 4B).
No GFP was observed in cells of the outer retina.
While GFP-expressing cells were found throughout the
retinas after intravitreal injection, the portion of the
retina exposed to the highest concentration of virus
(that region closest to the needle) had the highest
concentration of expressing cells. GFP-expressing gan-
glion cell axons could be traced through their exit of
the retina within the optic nerve (Fig. 3A–C). High
levels of histologically detectable GFP persisted in eyes
receiving subretinal or intravitreal AAV–GFP at least
7.5 months after injection (the latest timepoint). Fluo-
rescence was not detected in control-injected retinas or
optic nerves at any timepoint (Fig. 3D, E). There was
no evidence of inflammation or cellular infiltrate at any
timepoint as assessed by counterstaining sections with
hematoxylin and eosin or neutral red.
Whole mount examination of dissected mouse and
dog brains from AAV–GFP-injected animals revealed
the presence of fluorescing axons within the optic
nerves and chiasm (Fig. 3F, G; Fig. 4C). Fluorescent
decussating fibers could be identified in the optic chi-
asm as well as bead-like fluorescent out-pouchings ema-
nating from the linear axons (see arrows, Fig. 3G). No
other surface structures of the brain possessed GFP-re-
lated fluorescence. Histological assessment of the brains
revealed high levels of transgene expression in multiple
tracts originating and branching from the optic nerves.
Identification of transgene-expressing structures within
the mouse brain was performed through identification
of anatomical landmarks delineated in an atlas of the
C57Bl:6 mouse brain (Franklin & Paxinos, 1997). As
shown in Fig. 5A–D, fluorescent axons were also ob-
served in radiations as well as within the superior
colliculi (Fig. 5C–F) and the laterogeniculate nuclei
(Fig. 5H–K). Expression was often bilateral (even in
mice in which AAV was injected unilaterally) due to
decussations of the optic nerves at the optic chiasm.
GFP was also detected in the suprachiasmatic nuclei,
the paraventricular nuclei and the supraoptic nuclei.
GFP was also observed in the dog brain, in the same
optic nerve tracts as observed in mice (shown is the
suprachiasmatic nucleus, Fig. 4D). GFP expression was
not detected in secondary neurons or in other portions
of the brains of mice or dogs. No GFP fluorescence was
detected in control retinas or optic nerves. Similar to
Fig. 3. (Opposite, bottom) Light (A) and fluorescent (B) views of mouse optic nerve 3 months after subretinal injection of AAV–GFP. Note that
axons in only one portion of the optic nerve possess GFP. (C) Higher magnification view of GFP-expressing optic nerve. (D, E) Light (D) and
fluorescent (E) views of optic nerve from a control (vehicle-injected) eye 3 months after injection reveal a lack of fluorescent axons. (F) Whole
mount view of optic nerves (arrows) and chiasm (X) at base of brain. (G) A higher magnification view of (F). Arrows in (G) indicate bead-like
fluorescent outpocketings extending from axons within the optic nerve. (A–C) 480; (D–H) 60; (I) 100; (J) 150.
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Fig. 4. Caption opposite.
Fig. 5. Caption opposite.
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Fig. 6. ELISA for IgG to AAV in serum from mice and dogs receiving intraocular injection of AAV–GFP. (A) Analyses of mice that had received
subretinal injection of 1109 iu AAV–GFP, AAVbcl-2, Ad.GFP and AAVGFP reveals a slight increase in the Ig(G2bG3) antibody (as
measured by A405) over control in all animals. Numbers indicate average absorbance in cohorts of animals. Positive controls include a mouse
receiving the same amount of rAAV by intramuscular injection (as described by Fisher, Jooss, Alston, Yang & Haecker, 1997) and serum from
a human with antibodies versus AAV. *Statistically significant difference compared to negative control (P0.001); **PB0.0001. (B) Analyses
of antibody responses in dogs that had received subretinal injection of 1.91010 iu AAV in the right eyes and intravitreal injection of 9.41010
iu AAV–GFP in the contralateral (left) eyes. Serum analysis revealed a mild increase in humoral response in comparison of pre- and
post-treatment samples, similar to that observed in mice. A mild humoral response was also observed in anterior chamber fluid samples of eyes
receiving subretinal or intravitreal AAV.
the retinas, there was no clinical or histological evi-
dence of inflammatory response in brains of animals
injected intraocularly with rAAV.
In order to determine whether GFP expression in the
CNS related specifically to the rAAV vector, retinal
and CNS-specific transgene expression patterns were
analyzed in a group of ten mice injected with a recom-
binant adenovirus carrying the identical transgene cas-
sette as rAAV–GFP. As expected given previous
descriptions of retinal cell types targeted by recombi-
nant adenovirus (Bennett, Wilson, Sun, Forbes &
Maguire, 1994; Li, Adamian, Roof, Berson & Dryja,
1994), high levels of GFP were detected in RPE cells
and Muller cells and in occasional photoreceptor cells
within 24 h after injection. Intravitreal injection re-
sulted in GFP expression by Muller cells and cells of
the anterior segment. No GFP-expressing ganglion
cells, optic nerves or brains were observed after subreti-
nal or intravitreal administration of Ad.CMVGFP.
3.3. Immune response to adeno-associated 6irus capsid
proteins:green fluorescent protein
Previous studies on mice have demonstrated that
intraocular delivery of adenovirus at the doses used
does not result in significant systemic humoral response
Fig. 4. (Opposite, top) Similar transduction patterns are observed in dogs as in mice after subretinal or intravitreal administration of rAAV–GFP.
(A) Subretinal injection of AAV–GFP results in photoreceptor-specific transgene expression. (B) AAV–GFP transduces retinal ganglion cells and
results in transgene expression in the optic nerve (C) and the brain (D) of dog after intravitreal injection. (A) GFP-expressing photoreceptors are
apparent 7 weeks after subretinal injection of 1.91010 iu rAAV–GFP. Arrow depicts a GFP-expressing region; (B) GFP expression is apparent
in a representative ganglion cell of an eye that had received an intravitreal injection of 9.41010 iu rAAV–GFP 3 weeks earlier; GFP expression
can be traced through the optic nerve to the optic chiasm (C), where GFP-expressing axons from the contralateral injected eye are also observed
(arrows indicate directions of optic nerves toward the chiasm). (D) GFP expression is observed in the suprachiasmatic nuclei in the brain of this
dog.
Fig. 5. (Opposite, bottom) Retinofugal pathways are demarcated by GFP after intraocular injection of AAV–GFP in the mouse. High levels of
transgene expression are observed in radiations of the optic tract in coronal sections of brains of mice injected intravitreally with rAAV–GFP
(A–D). GFP-mediated fluorescence is observed in the optic nerve itself (panel G, arrow), at the entry of the optic nerve tract at the base of the
brain (B), as well as in fibers leading to the superior colliculus (‘sc’; C, D). A more anterior view of GFP-expressing fibers in the superior colliculus
(arrowhead) is observed in panel F. High levels of GFP expression are also observed in the optic tract leading to the laterogeniculate nucleus as
well as within this structure (I–K). Rectangles drawn in the cartoons indicate the areas under view in accompanying panels as follows: cartoon
A, small rectangle, panel B; cartoon A, large rectangle, panel C and (at higher magnification) panel D; cartoon E: rectangle, panel F; cartoon H:
rectangle, area of view in I–K. (J, K) Higher magnification views of the inferior an superior portions, respectively of the laterogeniculate nucleus
depicted in panel I. Black regions in cartoons represent ventricles. (B, C, D, F, G) 100; (I, J) 220.
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(Bennett et al., 1996). In order to assess the immunolog-
ical consequences of intraocular injection of rAAV, we
performed studies on serum samples of mice and on
serum and anterior chamber fluids of dogs injected
subretinally or intravitreally with rAAV. Subretinal and
intravitreal injection of AAV–GFP or AAV-bcl-2 re-
sulted in a small but statistically significant increase in
Ig(G2bG3) in serum over control (P0.001)(Fig.
6A). IgG2a antibodies were not detected (data not
shown). Therefore, the immune response directed against
AAV capsid proteins is a Th-2 (or Th-1 independent)
response. The serum results in dogs paralleled those of
the mice (Fig. 6B). In addition, a small but reproducible
antibody response (again Th-2) was detected through
analyses of intraocular fluid samples.
Finally, humoral response to GFP itself was assessed
by Western analysis in serum and intraocular fluid
samples from dogs and serum samples from mice.
Antibodies to GFP were not detected in mice by this
method but were present in high levels in serum only in
the dog (c1219) which received the higher dose of virus
(lane 4 of Fig. 7 and data not shown).
4. Discussion
This study provides the first description of the ability
to use rAAV to deliver a transgene product to the brain
via ocular (ganglion cell) administration. Intraocular
delivery of recombinant adenovirus, which does not
transduce ganglion cells efficiently, does not result in
delivery of the transgene product to the CNS. Ganglion
cells, however, are transduced efficiently after intraocular
(intravitreal) delivery of rAAV. After intraocular injec-
tion of rAAV–GFP, GFP is detected in CNS tissues
known to be enervated by retinal ganglion cells (Glaser
& Sadun, 1990). This effect is not species-specific as
similar results were obtained in the dog and in the mouse.
Neither is the result dependent on surgical approach as
the same effect was observed after transscleral:tran-
schoroidal delivery as after delivery through a transvit-
real approach.
The anatomical pathways connecting the retinal gan-
glion cells to the CNS have been well-documented
through studies involving orthograde and retrograde
transport of a variety of compounds, including labeled
amino acids and proteins, histologically detectable en-
zymes (such as horseradish peroxidase) and fluorescent
compounds. The molecules enter the retinal ganglion
cells through internalization or can be delivered through
microinjection (of individual cells). Retinal ganglion cell
labeling mediated by rAAV, described here, is efficient,
has minimal toxicity and selectively delivers the transgene
to retinal ganglion cells (after intravitreal injection).
Delivery of a protein (transgene product) through trans-
duction with rAAV also presents two other advantages
over traditional methods of introducing proteins into
retinal ganglion cells. (1) Delivery of DNA encoding the
transgene presents the possibility that the foreign protein
can be produced continuously (as long as the transgene
is transcribed). (2) Production of the protein product by
the retinal ganglion cells themselves (and elimination of
the internalization:transport steps) is likely to minimize
the significant degradation that is observed after internal-
ization of protein (Johnson, Andres & Bradshaw, 1978;
Ferguson, Schweitzer & Johnson, 1990). Both Johnson
et al. and Ferguson et al. have demonstrated that proteins
delivered to retinal ganglion cells by internalization
undergo proteolytic cleavage within minutes to hours.
Such processes lead to loss of biological function.
In the study presented here, we have demonstrated that
the GFP protein is stable in the transduced cells and
delineates their anatomical pathways for at least 7.5
months after injection. There is no detectable humoral
response to the transgenic protein. The antibody re-
sponse to the rAAV capsid protein is Th-1-independent.
This indicates that the cellular immune response to the
vector is minimal, a fact supported by the lack of
histological evidence of inflammation after injection of
rAAV. These results suggest that rAAV may be a
powerful tool with which to label or experimentally
manipulate retinal ganglion cell targets in the brain. The
results from the present study relate specifically to an
intracellular cytoplasmic protein (GFP). What remains
to be seen is whether AAV-mediated transgene delivery
can be used to deliver intact membrane-bound or
secreted proteins to the CNS. The ability of intraocularly
delivered AAV to deliver secreted proteins to the brain
is particularly attractive as the proteins would be biolog-
ically active beyond the distances traversed by the axons
themselves. This possibility is currently under investiga-
tion in our laboratory.
Several exciting prospects will emerge should intraoc-
ular delivery of rAAV be capable of delivering biologi-
Fig. 7. Western blot analysis reveals antibody to GFP in post-
treatment serum of one dog. Post-treatment samples were obtained
7 weeks after injection. Lanes 1, 2: pre-and post-immune serums of
dog c1400; lanes 3, 4: pre- and post-immune serums, respectively of
dog c1219; lanes 5, 6: pre-and post-immune intraocular fluid of dog
c1219. Sizes of protein markers (kDa) are indicated at left. Arrow
indicates 28 kDa band corresponding to GFP. Methods are described
in the text.
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cally active proteins to the brain. This virus could be
used to deliver experimental compounds to specific
portions of the optic nerve:brain in order to generate
animal models for specific diseases. In addition, such
results would also have important implications with
respect to therapeutic applications of rAAV. It may
be possible to harness rAAV as a vector with which
to deliver genes therapeutic for such diseases as optic
neuropathies, brain tumors and metabolic disorders.
The current findings also have important implica-
tions with respect to retinal gene therapy. Rescue of
photoreceptors degenerating due to inherited retinal
degeneration will likely require subretinal injection as
this results in efficient transduction of these cells. The
results indicate that even though subretinal injection
primarily exposes cells of the outer retina, a sufficient
amount of virus escapes into the vitreous cavity so
that inner retinal ganglion cells are also transduced.
Transgenes aimed at delivering therapeutic molecules
to the retina may result in toxicity to the central
nervous system. Incorporation of photoreceptor or
RPE-specific promoters could be used to limit trans-
gene expression to cells of the outer retina in retinal
gene therapy. These promoters should be sufficient, if
the transgene:virus:transgene product is not transmit-
ted trans-synaptically. We have found no evidence of
trans-synaptic transmission of virus, as there is no
transgene expression beyond the first synapse of the
transduced cells.
Finally, results from this study confirm earlier find-
ings relating to the stability and efficiency of rAAV-
mediated transduction of neuronal cells-particularly of
photoreceptors. Interestingly, while minimal evidence
of inflammatory response is observed, ocular adminis-
tration of rAAV results in a small but significant in-
crease in rAAV-specific antibody response
systemically. A small rAAV-specific antibody response
is also observed within the intraocular fluid (of the
dog). Interestingly, one of the dogs also possessed a
strong systemic (but not intraocular) antibody re-
sponse to the GFP protein. Experiments, in progress,
will determine whether presence of anti-AAV anti-
body is sufficient to neutralize subsequent administra-
tion of vector. Additional studies will reveal whether
antibody response to the transgene product itself will
limit utility of intraocular gene delivery. These issues
will be important for studies designed to treat slowly
progressive inherited retinal degenerations like retinitis
pigmentosa.
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